Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 250

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 250
---
 with any broker, finder or investment banker, provided that the foregoing                                                                                                                     
 shall not prohibit the Company from entering into an agreement on commercially reasonable terms with any dealer and proxy solicitation services firm for purposes of soliciting proxies in connection with the Arrangement; or |

| (II) | not announce an intention, enter into any formal or informal agreement, or otherwise make a commitment to do 
 any of the things prohibited by any of the foregoing subsections.                                            |

| (c) | Notwithstanding the foregoing, the Company shall be entitled, but is under no obligation, to sell, transfer,                                                                                                                                                                                                                                                                                                                                     
 license, assign or otherwise divest any or all of the Company’s and its Subsidiary’s rights, Intellectual Property, and other assets related to (i) the RP-3467 program, a Polq ATPase Inhibitor, (ii) the RP-1664 program, a polo-like kinase 4 (PLK4) inhibitor, (iii) the RP-3500 (Camonsertib)                                                                                                                                               
 program, an ATR inhibitor, and/or (iv) [***], in one or more transactions (each a “Permitted Disposition” and collectively, the “Permitted Dispositions”) prior to the Effective Date; provided, however, that if any                                                                                                                                                                                                                            
 such Permitted Disposition results in the imposition of ongoing obligations (including indemnification obligations or potential post-closing claims for breach of contract) or liabilities on the Company or the Subsidiary, the terms of the Permitted                                                                                                                                                                                          
 Disposition relating to such obligations or liabilities shall be acceptable to the Purchaser, acting reasonably, it being acknowledged that any such Permitted Disposition that is without recourse to the Company (such as an as-is transaction or one where post-closing liability is limited solely to escrowed sale proceeds (together with a sole and exclusive remedy clause confirming the same) or one where recourses of the applicable 
 purchaser are limited solely to rights and recourses under a representations and warranties insurance policy (together with a sole and exclusive remedy clause confirming the same), coupled with a waiver of subrogation rights in favour of the Company                                                                                                                                                                                        
 and its Subsidiary) and does not impose any obligations or liabilities on the Company or its Subsidiary beyond those obligations                                                                                                                                                                                                                                                                                                                 |

A-31

| and liabilities outstanding as at the date hereof, shall be deemed acceptable to the Purchaser. The Parties acknowledge that the Company may not